This study aimed to compare and evaluate the efficacy of the blood pressure (BP) control
and cholesterol‐lowering effects and safety of combination therapy with telmisartan …

Single risk factors, such as hypertension and dyslipidemia, can combine to exacerbate the
development and severity of cardiovascular disease. Treatment goals may be more …

Purpose Fixed-dose combination therapy with telmisartan, amlodipine, and rosuvastatin is
needed in patients with hypertension and dyslipidemia for better adherence and cost …

Purpose Dyslipidemia and hypertension increase the risk for cardiovascular disease.
Combination therapy improves patient compliance. This study was conducted to compare …

Background: The introduction of a fixed-dose combination (FDC) is expected to improve
treatment compliance. Methods: There were 181 subjects who were randomized to three …

Purpose Hypertension and dyslipidemia are 2 risk factors of cardiovascular disease that
often present simultaneously. Traditionally, treatment of these multiple conditions required …

Abstract This multicenter, phase 4, Prospective Randomized Open, Blinded End‐point
(PROBE) study aimed to evaluate safety and efficacy of telmisartan/rosuvastatin single‐pill …

Background Hypertension and dyslipidemia significantly contribute to cardiovascular
disease development. Their coexistence poses challenges in managing multiple …

Abstract Saga Telmisartan Aggressive Research (STAR) is a single-arm, prospective multi-
center trial to evaluate the effectiveness of treatment with telmisartan in patients with …

Objective: Combination therapy may help achieve low-density lipoprotein cholesterol (LDL-
C) goals in high-risk patients. In this respect, the role of Rosuvastatin and Ezetimibe (RE) …